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Abstract Glycosaminoglycans regulate angiogenesis by affect-
ing the availability of different growth factors for the endothelial
cell (EC). However, little is known about the molecular and
functional consequences resulting from direct interaction of these
polyelectrolytes with the EC. Here we show that heparin
markedly inhibited serum-stimulated DNA synthesis and or-
nithine decarboxylase (ODC) mRNA expression in human
endothelial cells (HEC). About 50% of the serum effect on
DNA synthesis and ODC gene expression was prevented by the
selective protein kinase C (PKC) inhibitor chelerythrine or by
PKC down-regulation. Heparin was ineffective in counteracting
that part of the effect of serum that was resistant to PKC
inhibition or down-regulation. In serum-free cultured HEC,
heparin completely abolished the increase in DNA synthesis and
ODC mRNA expression elicited by a number of PKC activators.
Cell exposure to difluoromethylornithine, an irreversible inhibi-
tor of ODC enzyme, dramatically antagonised both serum- and
phorbol 12-myristate 13-acetate (PMA)-stimulated DNA syn-
thesis. These results suggest that inhibition of PKC-mediated
ODC gene expression by glycosaminoglycans may represent an
important mechanism in the regulation of HEC proliferation.
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1. Introduction
The endothelial cell (EC) plays a crucial role in the integra-
tion and modulation of signals within the blood vessel wall.
EC-released growth factors, including basic ¢broblast growth
factor (bFGF), endothelial cell growth factor (ECGF), trans-
forming growth factor (TGF), insulin like growth factor-1
(IGF-I), nitric oxide (NO) and endothelin [1^6], have been
shown to control cellular migration and proliferation in the
course of atherogenesis and in£ammatory responses [8]. EC is
also the target cell for tumour neovascularization [8], a proc-
ess which closely associates with tumour growth and meta-
stasis [9].
Glycosaminoglycans, including heparin (H) and heparan
sulphate (HS), exert remarkable e¡ects on angiogenesis
[10,11] and have been shown either to inhibit or to promote
EC proliferation [12,13]. Most of the glycosaminoglycan-in-
duced e¡ects have been attributed to their ability to a¡ect the
amount of growth factors available at the EC surface [14,15]
or the interaction of growth factors with the EC [16,17]. In
this regard, bFGF is bound to HS in the extracellular matrix
(ECM) and is released in an active form when ECM-HS is
degraded by cellular heparanase [15,18]. Therefore, restriction
of growth factor availability by binding to ECM glycosami-
noglycans and local regulation of growth factor release have
been regarded as mechanisms accounting for the e¡ects elic-
ited by glycosaminoglycans on angiogenesis under normal or
pathological conditions [19]. HS has also been shown to pro-
mote angiogenesis by increasing EC response to ECGF [20]
through a mechanism involving ECGF receptor occupancy
[21]. On the other hand, glycosaminoglycans have been shown
to bind to cell-surface receptors on EC and to be internalised
[22]. These ¢ndings raise the possibility that glycosamino-
glycans may regulate angiogenesis by directly acting extra-
cellularly and/or intracellularly on EC.
While the roles of glycosaminoglycans have been investi-
gated in many cell types, there are surprisingly few reports
detailing their e¡ects on EC function. In contrast to our
understanding on the e¡ects of glycosaminoglycans on growth
factor-modulated angiogenesis, comparatively little is known
about the molecular sequelae of events resulting from glycos-
aminoglycan interaction with EC. In the present study, we
provided details of the action of H and HS on EC, from their
direct e¡ects on DNA synthesis to the analysis of the possible
signal transduction pathway(s) involved in polyelectrolyte ac-
tion. The molecular dissection of the e¡ects of glycosamino-
glycans on EC function was further expanded by investigating
whether these polyelectrolytes may in£uence the expression of
a target gene in cell proliferation. In particular, we decided to
assess the e¡ects produced by H on the expression of the EC
ornithine decarboxylase (ODC) gene, which encodes for
ODC, the initial rate limiting enzyme in polyamine synthesis
[23,24]. This was done because the ODC gene has been shown
to be overexpressed in many growth processes and since pro-
liferative events [25^27] including angiogenesis [28,29] have
displayed an absolute requirement for both ODC activity
and polyamine biosynthesis [30,31].
2. Materials and methods
2.1. Cell culture
HEC were isolated from human umbilical cords and cultured as
previously described [32]. Brie£y, HEC were detached from the inter-
ior of the umbilical vein of a 30-cm segment of cord by treatment for
10 min at 37‡C with 0.05% (w/v) collagenase Type II from Clostridium
hystolyticum (Gibco BRL, Paisley, UK) in medium M199 (Gibco
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BRL, Paisley, UK) containing 100 units/ml of penicillin G sodium salt
and 100 Wg/ml streptomycin sulphate (Sigma Chemical Co., St. Louis,
MO, USA). HEC were harvested at 1000Ug for 10 min and ¢nally
resuspended in 5 ml of medium M199 supplemented with 10% (v/v)
FCS, 10% (v/v) newborn-calf serum (Gibco BRL, Paisley, UK), 2 mM
glutamine and antibiotics as above. Cells were then plated in 25 cm2
tissue culture £asks (Falcon, Oxnard, CA, USA) and cultured in an
atmosphere of 5% CO2/95% air. When con£uent, HEC were subcul-
tured at a split ratio of 1:2 by a brief treatment with 0.1% trypsin plus
0.02% EDTA in phosphate bu¡ered saline (PBS) (120 mM NaCl, 2.5
mM KCl, 8.5 mM NaH2PO4, 1.5 mM KH2PO4), pH 7.3. Cultured
cells were identi¢ed as endothelial by their typical cobblestone appear-
ance and production of von Willebrand factor as measured by en-
zyme-linked immunosorbent assay [33]. Cell viability was checked by
the trypan blue-exclusion method and used within three passages. In
each experiment, HEC were plated at a density of 70 000 cells/ml in
24-well plates (Falcon, Oxnard, CA, USA). After 48 h, the medium
was replaced and cells were synchronised following a 48-h incubation
in serum-free medium M199 containing 0.2% (w/v) bovine serum al-
bumin (BSA) (Sigma Chemical Co., St. Louis, MO, USA).
2.2. Determination of cell cycle progression and radioactivity
counting
Synchronised HEC were stimulated to growth in 24-well plates in
the presence of medium M199, containing 5% (v/v) FCS. For deter-
mination of entry into S phase, cells were pulse-labelled with 1 WCi/ml
[3H]thymidine (speci¢c activity 5 Ci/mmol, Amersham International
plc, Bucks, UK) for 1 h at 3-h intervals. At the indicated time points,
the medium was removed and the cell monolayer in each well was
washed twice with PBS (1 ml), exposed to 5% (v/v) trichloroacetic acid
(500 Wl) for 5 min, then ¢xed in methanol (500 Wl). Finally, the cells
were digested by the addition of 25 M formic acid (500 Wl). Each
formic acid digest was transferred with one rinse of PBS (1 ml) to a
scintillation vial containing 3.5 ml of INSTA-GEL scintillation £uid
(Packard Instruments Co., Meriden, CT, USA), and radioactivity was
determined by liquid scintillation counting [34] using a Wallac 1215
RackBeta liquid scintillation counter (LKB Instrument Inc., Gaithers-
burg, MD, USA).
2.3. Drug treatment and determination of DNA synthesis
Synchronised HEC were stimulated to growth for 48 h in the pres-
ence of medium M199, containing 5% (v/v) FCS (group A) or in a
serum-free medium M199 containing di¡erent PKC activators [35],
including phorbol 12-myristate 13-acetate (PMA) or phorbol 12,13-
dibutyrate (PDBu) (Sigma Chemical Co., St. Louis, MO, USA) (group
B). During the ¢rst 24 h, cells from each experimental group were
exposed to the indicated concentrations of H or HS (from porcine
intestinal mucosa, Sigma Chemical Co., St. Louis, MO, USA). Then,
HEC were washed once in serum-free medium M199 (1 ml/well) and
either reincubated with 5% (v/v) FCS-supplemented medium (group
A) or cultured in serum-free medium M199 (group B) for the remain-
ing 24 h. During this period HEC were added with 1 WCi/ml
[3H]thymidine. At the end of each experiment, cells were washed twice
with ice-cold PBS (1 ml/well) and processed for liquid scintillation
counting as above.
2.4. RNA extraction and determination of ODC mRNA
Synchronised subcon£uent HEC grown in 25-cm2 culture £asks
(Falcon, Oxnard, CA, USA) were treated as indicated in the ¢gure
legends. Total RNA extraction [36] was performed at the indicated
time points and the levels of ODC mRNA were assessed by using a
sensitive solution hybridisation RNase protection assay [37,38].
Brie£y, a 290-bp fragment puri¢ed from the full length cDNA coding
for rat ODC was cloned in the transcription vector pGEM7z. Tran-
scription of the plasmid linearized with ApaI (Boehringer Mannheim,
Mannheim, Germany) generated a sense strand of ODC mRNA used
to construct a standard curve of ODC mRNA, whereas transcription
of the plasmid linearized with BamHI (Boehringer Mannheim, Mann-
heim, Germany) in the presence of [32P]CTP (speci¢c activity 800 Ci/
mmol, Amersham International plc, Bucks, UK) gave an antisense
strand used to hybridise cellular ODC mRNA. The protected frag-
ments were recovered after phenol chloroform extraction and electro-
phoretically separated in a polyacrylamide non-denaturing gel. The
individual bands were counted for radioactivity by liquid scintillation
spectrometry (LKB Instrument Inc., Gaithersburg, MD, USA), and
cpm values were translated to pg values on a correlated standard
curve. Data were expressed as pg of speci¢c mRNA/Wg of total
mRNA.
2.5. Other cell treatments
Protein kinase C (PKC) down-regulation was accomplished by ex-
posing HEC to serum-free medium M199 containing 1 WM PMA
(Sigma Chemical Co., St. Louis, MO, USA) during the last 24 h of
cell synchronisation. The PKC inhibitors chelerythrine or calphostin
C (Alexis Corp., San Diego, CA, USA) were added at a concentration
of 2.5 WM and 1 WM respectively, during the last 4 h of cell synchro-
nisation. Di£uoromethylornithine (DFMO) experiments were per-
formed as indicated in the ¢gure legends.
2.6. Statistical analysis
The statistical analysis of the data was performed by using the
unpaired Student’s t-test, assuming a P value less than 0.05 as the
limit of signi¢cance. Data are expressed as mean þ S.E.M.
3. Results
To assess the cell entry into the S phase, cell cycle progres-
sion was analysed in HEC by pulse labelling in the presence of
[3H]thymidine. HEC were made quiescent by incubation in
serum-free medium M199 for 48 h. Fig. 1A shows the time-
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Fig. 1. A: Time-course of [3H]thymidine incorporation in HEC ex-
posed to 5% FCS. Synchronised HEC were stimulated to growth in
the presence of 5% FCS. Cells were pulse-labeled with 1 WCi/ml
[3H]thymidine for 1 h at 3-h intervals for the determination of cell
entry into the S phase. At the indicated time points, cells were
washed twice with ice-cold PBS and processed for liquid scintillation
counting as described in Section 2. Data represent the mean þ
S.E.M. of three di¡erent experiments. B: E¡ect of heparin (H) and
heparan sulphate (HS) on FCS-stimulated DNA synthesis. Cell ex-
posure to the indicated concentrations of each polyelectrolyte was
performed as described in Section 2 (white: control; diagonally
hatched: H; black: HS). Cells were processed for liquid scintillation
counting as described in Section 2. Data represent the mean þ
S.E.M. of six di¡erent experiments. *: signi¢cantly di¡erent from
the control value; ^ * ^: signi¢cant di¡erence between two groups.
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course of [3H]thymidine incorporation into DNA in HEC ex-
posed to 5% FCS, after release from a quiescent, growth-ar-
rested state (G0) which was con¢rmed by the low level of
thymidine incorporation during the ¢rst 12 h (5% FCS proved
to be the most e¡ective concentration in stimulating DNA
synthesis over a 0.01^20% range; data not shown). After a
24-h lag period corresponding to G1 phase, the rate of DNA
synthesis progressively increased up to 36^38 h (S phase), then
declined during the following 10 h (Fig. 1A). Therefore, in all
the experiments [3H]thymidine was administered between 24
and 48 h.
To determine the e¡ect of di¡erent polyelectrolytes on
DNA synthesis, quiescent HEC were stimulated to leave the
growth-arrested state by incubation for 48 h in medium
M199, supplemented with 5% (v/v) FCS, and treated with H
or HS (50^200 Wg/ml range) for the ¢rst 24 h of this period.
Fig. 1B shows that both H and HS signi¢cantly inhibited
serum-induced DNA synthesis. Such an e¡ect was evident at
a concentration of 50 Wg/ml and peaked at a concentration of
200 Wg/ml. Both the selective PKC inhibitor chelerythrine
[39,40] and a long-term exposure to PMA, an intervention
leading to PKC down-regulation [41], elicited more than
50% reduction in the serum-stimulated DNA synthesis (Fig.
2). However, these treatments were ine¡ective in completely
abolishing the e¡ect of FCS (Fig. 2). The addition of H to
chelerythrine-treated or to PKC-down-regulated HEC failed
to produce any additive inhibition of the e¡ect of FCS (Fig.
2). In the absence of serum, the PKC activators PDBu or
PMA elicited a marked and dose-dependent increase in
[3H]thymidine incorporation (Fig. 3). In addition, each acti-
vator did not a¡ect DNA synthesis in the presence of cheler-
ythrine or in PKC down-regulated cells (Fig. 3). When HEC
were exposed for 24 h to the above mentioned PKC activators
in the presence of either H or HS, each polyelectrolyte was
able to completely antagonise the stimulatory e¡ect induced
by each phorbol ester on DNA synthesis (Fig. 4).
The exposure of HEC to 5% FCS elicited a time-dependent
increase in ODC mRNA expression (Fig. 5A). This stimula-
tory e¡ect was evident after 1 h of treatment and reached a
maximum at 2 h. Thereafter, ODC mRNA levels progres-
sively declined and returned to the control value at 12 h.
Fig. 5B shows that the addition of 200 Wg/ml H to the incu-
bation medium signi¢cantly, although not completely, inhib-
ited serum-stimulated ODC gene expression. A partial signi¢-
cant inhibition of serum-induced ODC gene expression was
also observed in chelerythrine-treated or in PKC-down-regu-
lated cells (Fig. 5C). Under these experimental conditions, no
further inhibition of the e¡ect of serum was observed follow-
ing the administration of H (200 Wg/ml) (Fig. 5C).
A time-dependent increase in ODC mRNA was also found
in serum-free HEC that had been exposed to PMA (Fig. 6A).
The phorbol ester-mediated event peaked at 2 h. However, at
this time point ODC mRNA levels were signi¢cantly lower
than those observed following a 2-h exposure to FCS. The
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Fig. 4. E¡ect of H and HS on PKC-mediated DNA synthesis in
HEC. Cell exposure to H or HS (200 Wg/ml) or to each PKC acti-
vator (100 nM) was performed as described in Section 2. 1: Un-
treated cells; 2: PDBu; 3: PDBu+H; 4: PDBu+HS; 5: PMA; 6:
PMA+H; 7: PMA+HS. Cells were processed for liquid scintillation
counting as described in Section 2. Data represent the mean þ
S.E.M. of six di¡erent experiments. *: signi¢cantly di¡erent from 1.
Fig. 3. E¡ect of di¡erent PKC activators on DNA synthesis in
HEC. Normal HEC, down-regulated cells (DR) or chelerythrine
(CHE)-treated cells were stimulated to growth for 48 h in the pres-
ence of serum-free medium M199. During the ¢rst 24 h, HEC were
incubated in the absence (E, control) or in the presence of the indi-
cated concentrations of PKC activators (a, PMA; O, PDBu; R,
DR+PMA; b, CHE+PMA). At the end of this period, the medium
was removed, cells were washed once with medium M199 and rein-
cubated for the last 24 h in the presence of serum-free medium
M199, containing 1 WCi/ml [3H]thymidine. Cells were processed for
liquid scintillation counting as described in Section 2. Data repre-
sent the mean þ S.E.M. of six di¡erent experiments. *, signi¢cantly
di¡erent from the control value.
Fig. 2. Inhibition of the FCS-stimulated DNA synthesis in HEC by
chelerythrine (CHE) (2.5 WM) or PKC down-regulation (DR). Un-
treated: growth-arrested HEC untreated; 5% FCS: HEC exposed to
5% FCS; DR+5% FCS: down-regulated HEC exposed to 5% FCS;
CHE+5% FCS: chelerythrine-treated HEC exposed to 5% FCS;
DR+5% FCS+H: down-regulated HEC exposed to 5% FCS plus
200 Wg/ml H; CHE+5% FCS+H: chelerythrine-treated HEC ex-
posed to 5% FCS plus 200 Wg/ml H. Cells were processed for liquid
scintillation counting as described in Section 2. Data represent the
mean þ S.E.M. of six di¡erent experiments. *: signi¢cantly di¡erent
from 5%.
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e¡ect elicited by PMA on ODC mRNA levels was dose-de-
pendent and was not observed in chelerythrine (CHE) or in
calphostin C (CAL)-treated cells. No increase in ODC mRNA
levels was detected following the addition of PMA to PKC
down-regulated cells or following HEC treatment in the pres-
ence of the inactive phorbol ester 4K-phorbol 12-myristate 13-
acetate (4K-PMA) (Fig. 6B). Cell exposure to 200 Wg/ml H
caused a complete suppression of the stimulatory e¡ect in-
duced by PMA or PDBu on ODC mRNA expression (Fig.
6C).
Fig. 7 shows that HEC treatment for 24 h in the presence of
5 mM di£uoromethylornithine (DFMO), an enzyme activated
irreversible inhibitor of ODC [42], markedly antagonised both
serum- and PMA-stimulated DNA synthesis.
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Fig. 6. A: Time course of the e¡ect of PMA on the ODC mRNA
expression in HEC. Synchronised subcon£uent HEC were stimulated
with 100 nM PMA. At the indicated time points, total mRNA was
extracted and processed for isolation and quanti¢cation. Data repre-
sent the mean þ S.E.M. of four di¡erent experiments. *: signi¢cantly
di¡erent from time 0. Representative autoradiograms of the ribonu-
clease protection analysis of ODC mRNA are shown in the inset.
B: Dose-response of PMA e¡ect on the expression of ODC mRNA.
Synchronised subcon£uent HEC were incubated in the presence of
each indicated concentration of PMA for a period of 2 h. Data rep-
resent the mean þ S.E.M. of four di¡erent experiments. *: signi¢-
cantly di¡erent from 0 nM PMA. 4K-PMA: synchronised subcon£u-
ent HEC stimulated for 2 h with 100 nM of the inactive phorbol
ester 4K-phorbol 12-myristate 13-acetate; DR+PMA: down-regu-
lated HEC stimulated for 2 h with 100 nM PMA; CHE+PMA:
chelerythrine-treated HEC stimulated for 2 h with 100 nM PMA;
CAL C+PMA: calphostin C-treated HEC stimulated for 2 h with
100 nM PMA. Data represent the mean þ S.E.M. of four di¡erent
experiments. Representative autoradiograms of the ribonuclease pro-
tection analysis of ODC mRNA are shown in the inset. C: E¡ect
of 200 Wg/ml H on PKC-mediated ODC mRNA expression in
HEC. PMA: synchronised subcon£uent HEC were stimulated for
2 h with 100 nM PMA; PMA+H: synchronised subcon£uent HEC
were stimulated for 2 h with 100 nM PMA plus 200 Wg/ml H;
PDBu: synchronised subcon£uent HEC were stimulated for 2 h
with 100 nM PDBu; PDBu+H: synchronised subcon£uent HEC
were stimulated for 2 h with 100 nM PDBu plus 200 Wg/ml H.
Data represent the mean þ S.E.M. of four di¡erent experiments. *:
signi¢cantly di¡erent from PMA; **: signi¢cantly di¡erent from
PDBu. Representative autoradiograms of the ribonuclease protec-
tion analysis of ODC mRNA are shown in the inset.
Fig. 5. A: Time course of the e¡ect of 5% FCS on the ODC
mRNA expression in HEC. Synchronised subcon£uent HEC were
stimulated with 5% FCS. At the indicated time points, total mRNA
was extracted and processed for isolation and quanti¢cation. Data
represent the mean þ S.E.M. of four di¡erent experiments. *: signi¢-
cantly di¡erent from time 0. Representative autoradiograms of the
ribonuclease protection analysis of ODC mRNA are shown in the
inset. B: E¡ect of heparin (H) on FCS-stimulated mRNA expres-
sion. Synchronised subcon£uent HEC were stimulated with 5% FCS
(C), or stimulated with 5% FCS plus 200 Wg/ml H (H). At the indi-
cated time points, total mRNA was extracted and processed for iso-
lation and quanti¢cation. Data represent the mean þ S.E.M. of four
di¡erent experiments. *: signi¢cantly di¡erent from C. Representa-
tive autoradiograms of the ribonuclease protection analysis of ODC
mRNA are shown in the inset. C: Inhibition of the FCS-stimulated
mRNA expression by chelerythrine (CHE) (2.5 WM) or PKC down-
regulation (DR). 5% FCS: HEC stimulated for 2 h with 5% FCS;
DR+5% FCS: down-regulated HEC stimulated for 2 h with 5%
FCS; CHE+5% FCS: chelerythrine-treated HEC stimulated for 2 h
with 5% FCS; DR+5% FCS+H: down-regulated HEC stimulated
for 2 h with 5% FCS plus 200 Wg/ml H; CHE+5% FCS+H: cheler-
ythrine-treated HEC stimulated for 2 h with 5% FCS plus 200 Wg/
ml H. Data represent the mean þ S.E.M. of four di¡erent experi-
ments. *: signi¢cantly di¡erent from 5% FCS. Representative auto-
radiograms of the ribonuclease protection analysis of ODC mRNA
are shown in the inset.
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4. Discussion
The endothelium is of major importance to the maintenance
of vascular homeostasis, due to its regulated secretion or sur-
face expression of modulators of a wide variety of physiolog-
ical processes [8]. Recently there has been much interest in the
mechanism of action of antiproliferative agents, with a variety
of studies showing that such agents may exert their e¡ect on
cell growth through the modulation of several genes [43]. De-
spite intense interest in the e¡ects of glycosaminoglycans on
cell proliferation, there are few reports describing such inves-
tigation using EC. Therefore we examined the e¡ects of H and
HS on serum- and phorbol ester-stimulated DNA synthesis in
HEC. Furthermore, we analysed the e¡ect of H on FCS- and
PMA-stimulated ODC mRNA levels, since the ODC gene has
been shown to be overexpressed in many growth processes
and proliferative events, closely related to angiogenesis. The
current experimental data show that both H and HS counter-
acted serum-stimulated DNA synthesis in HEC. In di¡erent
cell types, including HEC, vascular smooth muscle cells and
¢broblasts, PKC plays a crucial role in the modulation of cell
growth, being implicated both in proliferative and antiproli-
ferative responses [44,45]. Furthermore, phorbol ester sensi-
tive PKC isoforms have been detected in HEC [46,47]. The
present observation that both a PKC inhibitor and enzyme
down-regulation signi¢cantly reduced [3H]thymidine incorpo-
ration in serum-supplemented cells indicated that the e¡ect of
FCS on DNA synthesis may be at least in part mediated by
PKC activation. However, failure of PKC inhibition or deple-
tion of abolishing completely the FCS action indicates that
PKC-independent mechanisms may also be conceivable. In
this regard, both PKC-dependent and PKC-independent path-
ways have been implicated in the proliferative e¡ect of serum
in vascular smooth muscle cells [48]. The ¢nding that H did
not produce additive inhibition of the e¡ect of FCS in cheler-
ythrine-treated or PKC-depleted cells suggests that H might
have acted by suppressing a serum-activated PKC-dependent
pathway, being without e¡ect on DNA synthesis stimulated
by serum through PKC-unrelated events. The possibility that
inhibition of a PKC-dependent pathway may be a major sig-
nalling mechanism in the antiproliferative action of H was
further supported by the capability of this polyelectrolyte of
abolishing completely the stimulatory e¡ect elicited on DNA
synthesis by a number of PKC activators in a serum-free
medium. These results also suggest that the inhibitory e¡ect
of H on serum-induced [3H]thymidine incorporation is un-
likely to be attributable to interference of the polyelectrolyte
with growth factors or other factors in the serum. Rather, the
present observations support the possibility that H may have
interacted directly with HEC to a¡ect PKC-mediated events
involved in the regulation of HEC proliferation. Here we
show that both FCS and PMA were able to stimulate ODC
gene expression in HEC. ODC plays a rate limiting role in
polyamine biosynthesis and is intimately associated with cell
proliferation and function [49,50]. Moreover, an increase in
ODC gene expression has been observed in di¡erent cell types
in response to a number of proliferative agents, including
bFGF, serum and phorbol esters [27,49,51,52]. The present
observation that only part of FCS-induced overexpression
of ODC mRNA could be prevented by PKC inhibition or
down-regulation suggests that, similar to the FCS-mediated
increase in HEC DNA synthesis, the stimulation of ODC
gene expression induced by serum might have occurred
through di¡erent signal-transduction pathways, presumably
involving both PKC-dependent and PKC-independent mech-
anisms. Such a hypothesis is further supported by the obser-
vation that, di¡erently from the e¡ect of serum, the stimula-
tory e¡ect of PMA on ODC mRNA expression could be
totally abolished in chelerythrine-treated or PKC-down-regu-
lated cells and by the ¢nding that the peak increase in ODC
mRNA levels in the presence of PMA was signi¢cantly lower
than that observed in serum-stimulated cells.
A number of experimental observations in the present study
suggests the possibility that H might exert its antiproliferative
action on HEC by inhibiting a PKC-dependent pathway con-
trolling ODC gene expression. First, H markedly inhibited
serum-induced ODC gene expression to the same extent as
chelerythrine or PKC down-regulation. Second, the inhibitory
e¡ect of H was not additive to the down-regulation of ODC
mRNA induced by PKC inhibition or depletion in serum-
supplemented cells, indicating that each of these treatments
and the polyelectrolyte might have inhibited ODC gene ex-
pression by following the same signal-transduction pathway.
Third, similar to interventions aiming at inhibiting or down-
regulating PKC, HEC exposure to H completely suppressed
phorbol ester-induced ODC gene expression in serum-free
HEC. The fourth experimental observation is that HEC ex-
posure to the irreversible ODC inhibitor DFMO elicited a
dramatic decrease in both serum- and PMA-stimulated
[3H]thymidine incorporation. This ¢nding is in agreement
with other studies showing that serum-stimulated endothelial
cell proliferation could be nearly suppressed by inhibition of
polyamine synthesis [42] and further supports the hypothesis
that H, by inhibiting PKC-mediated ODC gene expression
might have a¡ected a crucial mechanism of regulation of
HEC proliferation.
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Fig. 7. E¡ects of di£uoromethylornithine (DFMO) on FCS- and
PKC-induced DNA synthesis in HEC. Synchronised HEC were cul-
tured for 24 h in medium M199 supplemented with 5% FCS or in a
serum-free medium containing 100 nM PMA. During this period,
each group of cells received 5 mM DFMO. HEC were then washed
once (1 ml/well) and reincubated for additional 24 h with 5% FCS
or serum-free medium in the presence of 1 WCi/ml [3H]thymidine.
At the end of each experiment, cells were washed twice with ice-
cold PBS (1 ml/well) and processed for liquid scintillation counting
as described above. 5% FCS: HEC exposed for 48 h to 5% FCS;
DFMO+5% FCS: HEC exposed to 5% FCS plus 5 mM DFMO
during the ¢rst 24 h, and reincubated in 5% FCS after washing;
PMA: serum-free HEC exposed for 24 h to 100 nM PMA;
DFMO+PMA: serum-free HEC exposed to 100 nM PMA plus
5 mM DFMO during the ¢rst 24 h, and reincubated in serum-free
medium M199 after washing. Data represent the mean þ S.E.M. of
¢ve di¡erent experiments. *: signi¢cantly di¡erent from 5% FCS;
**: signi¢cantly di¡erent from PMA.
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The possible implications of the present study remain to be
elucidated. However, it is now evident that the endothelial cell
plays a crucial role in angiogenesis [53] and that it might a¡ect
the growth and di¡erentiation of neighbouring cells [7]. As H
acts on endothelial cells that lie immediately adjacent to the
myocytes within the intact myocardium, it is conceivable that
the antiproliferative e¡ect of H reported here would a¡ect the
availability of endothelial cell-released growth factors from
the myocardial cell. In this regard, both endothelin and insu-
lin-like growth factors have been reported to trigger the acti-
vation of an early gene program as well as that of fetal genes
in cultured myocytes, thus switching myocyte growth from
hyperplasia to hypertrophy [54,55]. Akin to the paracrine
role of endothelial cell is the capability of nitric oxide to
spread out of its site of production in£uencing many di¡erent
tissue elements, including neuronal, glial and vascular ele-
ments, that are not necessarily in close anatomical juxtaposi-
tion [56].
The present ¢ndings, indicating that the antiproliferative
e¡ect of H may be largely dependent upon down-regulation
of PKC-mediated induction of the ODC gene may be of par-
ticular relevance in consideration of the angiogenic role of
polyamines in both normal and malignant tissues. In this re-
gard, intimal hyperplasia, a process which has been implicated
both in atherogenesis and in£ammatory responses, has been
shown to be drastically reduced by ODC inhibition [57]. Fur-
thermore, a large body of experimental evidence indicates that
tumour growth mainly depends on formation of new blood
vessels [9,58] and it is increasingly becoming evident that in-
hibition of polyamine synthesis strongly counteracts tumour-
induced angiogenesis [30,31]. Interestingly, the use of stable
transfected cells with an expression construct containing ODC
DNA has established a causative role for ODC overexpression
in the acquisition of a transformation phenotype related to
neoplastic development [59]. Considered together, these ¢nd-
ings suggest the possibility that the inhibitory e¡ect of H on
HEC ODC gene expression observed in the present study may
represent a prominent feature in the control of pathological
processes of the blood vessel wall and in the modulation of
angiogenic stimuli leading to neoplastic growth.
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